Dissecting maternal and fetal genetic effects underlying the associations between maternal phenotypes, birth outcomes, and adult phenotypes: A mendelian-randomization and haplotype-based genetic score analysis in 10,734 mother–infant pairs
dc.contributor.author | Chen, J | |
dc.contributor.author | Bacelis, J | |
dc.contributor.author | Sole-Navais, P | |
dc.contributor.author | Srivastava, A | |
dc.contributor.author | Juodakis, J | |
dc.contributor.author | Rouse, A | |
dc.contributor.author | Hallman, M | |
dc.contributor.author | Teramo, K | |
dc.contributor.author | Melbye, M | |
dc.contributor.author | Feenstra, B | |
dc.contributor.author | Freathy, RM | |
dc.contributor.author | Smith, GD | |
dc.contributor.author | Lawlor, DA | |
dc.contributor.author | Murray, JC | |
dc.contributor.author | Williams, SM | |
dc.contributor.author | Jacobsson, B | |
dc.contributor.author | Muglia, LJ | |
dc.contributor.author | Zhang, G | |
dc.date.accessioned | 2021-02-17T09:58:13Z | |
dc.date.issued | 2020-08-25 | |
dc.description.abstract | Background Many maternal traits are associated with a neonate’s gestational duration, birth weight, and birth length. These birth outcomes are subsequently associated with late-onset health conditions. The causal mechanisms and the relative contributions of maternal and fetal genetic effects behind these observed associations are unresolved. Methods and findings Based on 10,734 mother–infant duos of European ancestry from the UK, Northern Europe, Australia, and North America, we constructed haplotype genetic scores using single-nucleotide polymorphisms (SNPs) known to be associated with adult height, body mass index (BMI), blood pressure (BP), fasting plasma glucose (FPG), and type 2 diabetes (T2D). Using these scores as genetic instruments, we estimated the maternal and fetal genetic effects underlying the observed associations between maternal phenotypes and pregnancy outcomes. We also used infant-specific birth weight genetic scores as instrument and examined the effects of fetal growth on pregnancy outcomes, maternal BP, and glucose levels during pregnancy. The maternal nontransmitted haplotype score for height was significantly associated with gestational duration (p = 2.2 × 10−4). Both maternal and paternal transmitted height haplotype scores were highly significantly associated with birth weight and length (p < 1 × 10−17). The maternal transmitted BMI scores were associated with birth weight with a significant maternal effect (p = 1.6 × 10−4). Both maternal and paternal transmitted BP scores were negatively associated with birth weight with a significant fetal effect (p = 9.4 × 10−3), whereas BP alleles were significantly associated with gestational duration and preterm birth through maternal effects (p = 3.3 × 10−2 and p = 4.5 × 10−3, respectively). The nontransmitted haplotype score for FPG was strongly associated with birth weight (p = 4.7 × 10−6); however, the glucose-increasing alleles in the fetus were associated with reduced birth weight through a fetal effect (p = 2.2 × 10−3). The haplotype scores for T2D were associated with birth weight in a similar way but with a weaker maternal effect (p = 6.4 × 10−3) and a stronger fetal effect (p = 1.3 × 10−5). The paternal transmitted birth weight score was significantly associated with reduced gestational duration (p = 1.8 × 10−4) and increased maternal systolic BP during pregnancy (p = 2.2 × 10−2). The major limitations of the study include missing and heterogenous phenotype data in some data sets and different instrumental strength of genetic scores for different phenotypic traits. Conclusions We found that both maternal height and fetal growth are important factors in shaping the duration of gestation: genetically elevated maternal height is associated with longer gestational duration, whereas alleles that increase fetal growth are associated with shorter gestational duration. Fetal growth is influenced by both maternal and fetal effects and can reciprocally influence maternal phenotypes: taller maternal stature, higher maternal BMI, and higher maternal blood glucose are associated with larger birth size through maternal effects; in the fetus, the height- and metabolic-risk–increasing alleles are associated with increased and decreased birth size, respectively; alleles raising birth weight in the fetus are associated with shorter gestational duration and higher maternal BP. These maternal and fetal genetic effects may explain the observed associations between the studied maternal phenotypes and birth outcomes, as well as the life-course associations between these birth outcomes and adult phenotypes. | en_GB |
dc.identifier.citation | Vol. 17 (8), article e1003305 | en_GB |
dc.identifier.doi | 10.1371/JOURNAL.PMED.1003305 | |
dc.identifier.uri | http://hdl.handle.net/10871/124769 | |
dc.language.iso | en | en_GB |
dc.publisher | Public Library of Science (PLoS) | en_GB |
dc.rights | © 2020 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | en_GB |
dc.title | Dissecting maternal and fetal genetic effects underlying the associations between maternal phenotypes, birth outcomes, and adult phenotypes: A mendelian-randomization and haplotype-based genetic score analysis in 10,734 mother–infant pairs | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2021-02-17T09:58:13Z | |
dc.identifier.issn | 1549-1277 | |
dc.description | This is the final version. Available on open access from the Public Library of Science via the DOI in this record | en_GB |
dc.description | Data Availability: The data used in this study are available to other researchers. In order to respect and protect the interests and privacy of the research participants, the access to the individual-level phenotype and genotype data requires submitting applications to and approval by the corresponding entities who are in charge of the distribution of the data sets (e.g., FIN, ALSPAC, FIN, MoBa, and dbGaP). This is to ensure that the proposed study aims are consistent with the informed consent under which the data or samples were collected and appropriate data safety and security measures are in place to protect against data breach and unauthorized use. Individual-level phenotype and genotype data from the Finnish (Helsinki) birth cohort are available through the March of Dimes Prematurity Research Center Ohio Collaborative (http://prematurityresearch.org/ohiocollaborative/), and access will be approved by the Leadership Committee through its director of operations, Joanne Chappell (joanne.chappell@cchmc.org). ALSPAC data are available to scientists on request to the ALSPAC Executive Committee (ALSPAC-exec@bristol.ac.uk) or via website (http://www.bristol.ac.uk/alspac/researchers/access/), which also provides full details and distributions of the ALSPAC study variables. The detailed policy of data sharing can be found in the ALSPAC data management plan (http://www.bristol.ac.uk/alspac/researchers/data-access/documents/alspac-data-management-plan.pdf). MoBa data is available to researchers and research groups at both the Norwegian Institute of Public Health and other research institutions nationally and internationally. The research must adhere to the aims of MoBa and the participants' given consent. All use of data and biological material from MoBa is subject to Norwegian legislation. Terms for applying for access to data and links to the application form and information can be found at https://www.fhi.no/en/studies/moba/for-forskere-artikler/research-and-data-access/. Access to the DNBC (phs000103.v1.p1), HAPO (phs000096.v4.p1), and GPN (phs000714.v1.p1) individual-level phenotype and genetic data can be obtained through dbGaP Authorized Access portal (https://dbgap.ncbi.nlm.nih.gov/dbgap/aa/wga.cgi?page=login). The informed consent under which the data or samples were collected is the basis for determining the appropriateness of sharing data through unrestricted-access databases or NIH-designated controlled-access data repositories. | en_GB |
dc.identifier.journal | PLoS Medicine | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en_GB |
dcterms.dateAccepted | 2020-07-21 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2020-08-25 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2021-02-17T09:55:44Z | |
refterms.versionFCD | VoR | |
refterms.dateFOA | 2021-02-17T09:58:18Z | |
refterms.panel | A | en_GB |
refterms.depositException | publishedGoldOA |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2020 Chen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.